1. Home
  2. WY vs BIIB Comparison

WY vs BIIB Comparison

Compare WY & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Weyerhaeuser Company

WY

Weyerhaeuser Company

HOLD

Current Price

$21.69

Market Cap

18.0B

Sector

Real Estate

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$181.52

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WY
BIIB
Founded
1900
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.0B
24.2B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
WY
BIIB
Price
$21.69
$181.52
Analyst Decision
Buy
Buy
Analyst Count
9
23
Target Price
$29.78
$176.48
AVG Volume (30 Days)
6.0M
1.9M
Earning Date
10-30-2025
10-30-2025
Dividend Yield
3.87%
N/A
EPS Growth
N/A
N/A
EPS
0.46
10.97
Revenue
$7,072,000,000.00
$10,065,900,000.00
Revenue This Year
$0.04
$3.61
Revenue Next Year
$3.97
N/A
P/E Ratio
$47.48
$16.52
Revenue Growth
N/A
4.77
52 Week Low
$21.16
$110.04
52 Week High
$32.70
$185.17

Technical Indicators

Market Signals
Indicator
WY
BIIB
Relative Strength Index (RSI) 40.60 72.92
Support Level $21.22 $174.53
Resistance Level $22.47 $182.94
Average True Range (ATR) 0.51 5.22
MACD 0.05 0.25
Stochastic Oscillator 38.97 83.54

Price Performance

Historical Comparison
WY
BIIB

About WY Weyerhaeuser Company

Weyerhaeuser ranks among the world's largest forest product companies. Following the 2016 sale of its pulp business to International Paper, Weyerhaeuser operates three business segments: timberlands, wood products, and real estate. Weyerhaeuser is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities. Earnings from its wood products segment are subject to federal income tax. Weyerhaeuser acquired fellow timber REIT Plum Creek in 2016.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: